EA200800002A1 - Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt) - Google Patents

Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)

Info

Publication number
EA200800002A1
EA200800002A1 EA200800002A EA200800002A EA200800002A1 EA 200800002 A1 EA200800002 A1 EA 200800002A1 EA 200800002 A EA200800002 A EA 200800002A EA 200800002 A EA200800002 A EA 200800002A EA 200800002 A1 EA200800002 A1 EA 200800002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
pathological conditions
diseases
telbivoudina
klevududin
Prior art date
Application number
EA200800002A
Other languages
English (en)
Other versions
EA016838B1 (ru
Inventor
Юнг-Чи Ченг
Original Assignee
Йельский Университет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йельский Университет filed Critical Йельский Университет
Publication of EA200800002A1 publication Critical patent/EA200800002A1/ru
Publication of EA016838B1 publication Critical patent/EA016838B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals

Abstract

Настоящее изобретение относится к использованию соединения в соответствии с приведенной ниже формулой 1 для лечения опухолей, рака и гиперпролиферативных заболеваний, состояний или патологических состоянийгде Х обозначает Н или F; Rи Rнезависимо обозначают Н, ацильную группу, C-Cалкильную или эфирную группу, фосфатную, дифосфатную, трифосфатную или фосфодиэфирную группу, (А) или (В) группугде Nu обозначает радикал биологически активного соединения, такого как противораковое, противовирусное или антигиперпролиферативное соединение таким образом, чтобы аминогруппа или гидроксильная группа из указанного биологически активного компонента образовывала фосфатную, фосфорамидатную, карбонатную или уретановую группу со смежной частью; каждый Rнезависимо обозначает Н, или C-Cалкильную или эфирную группу, предпочтительно C-Cалкильную группу; k составляет 0-12, предпочтительно 0-2; и их фармацевтически приемлемые соли.
EA200800002A 2005-06-07 2006-06-05 Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt) EA016838B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68815905P 2005-06-07 2005-06-07
US74172805P 2005-12-02 2005-12-02
PCT/US2006/021742 WO2006133092A1 (en) 2005-06-07 2006-06-05 Methods of treating cancer and other conditions or disease states using lfmau and ldt

Publications (2)

Publication Number Publication Date
EA200800002A1 true EA200800002A1 (ru) 2008-08-29
EA016838B1 EA016838B1 (ru) 2012-07-30

Family

ID=37498764

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800002A EA016838B1 (ru) 2005-06-07 2006-06-05 Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)

Country Status (15)

Country Link
US (2) US7879816B2 (ru)
EP (1) EP1890537B1 (ru)
JP (1) JP5149168B2 (ru)
KR (1) KR101298631B1 (ru)
CN (1) CN103735560A (ru)
AU (1) AU2006255125B2 (ru)
BR (1) BRPI0613796A2 (ru)
CA (1) CA2609343C (ru)
EA (1) EA016838B1 (ru)
ES (1) ES2392544T3 (ru)
IL (1) IL187553A (ru)
MX (1) MX2007015534A (ru)
NZ (1) NZ563686A (ru)
SG (1) SG162753A1 (ru)
WO (1) WO2006133092A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808644A (zh) * 2007-05-11 2010-08-18 柏林自由大学 聚合酶抑制剂及其用于***的应用
EP1990054A1 (de) * 2007-05-11 2008-11-12 Freie Universität Berlin Polymerase-Hemmer und ihre Verwendung zur Behandlung von Tumoren
FR2924430B1 (fr) * 2007-11-30 2010-03-19 Univ Bordeaux 2 Procede de preparation de nanoparticules a base de molecules ou macromolecules amphiphiles fonctionnelles et leur utilisation
CN103221915B (zh) 2010-09-24 2017-02-08 国际商业机器公司 在开域类型强制中使用本体信息
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
PT107925A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
WO2016099982A2 (en) 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
AU2017281531A1 (en) 2016-06-24 2019-01-17 Emory University Phosphoramidates for the treatment of hepatitis B virus
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS525517B2 (ru) 1973-09-05 1977-02-14
JPS5123512B2 (ru) 1973-09-05 1976-07-17
JPS525518B2 (ru) 1973-10-15 1977-02-14
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS51146482A (en) 1976-05-28 1976-12-16 Taiho Yakuhin Kogyo Kk Process for preparing n1-(2- tetrahydrofuryl)-5-fluorouracil
JPS5384981A (en) 1976-09-03 1978-07-26 Taiho Pharmaceutical Co Ltd Method of producing 11*tetrahydroo22furanyl**55 fluorouracile
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
TW434252B (en) * 1997-07-23 2001-05-16 Univ Georgia Res Found Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine
US6054576A (en) * 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
PL363110A1 (en) * 2000-02-28 2004-11-15 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
JP2002217105A (ja) * 2001-01-17 2002-08-02 Sumitomo Chem Co Ltd ３−５族化合物半導体の製造方法
CN1646534A (zh) * 2002-02-14 2005-07-27 法玛塞特有限公司 修饰的氟化核苷类似物
US7291603B2 (en) * 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
MXPA05004919A (es) * 2002-11-06 2005-08-18 Cyclacel Ltd Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
BRPI0412031A (pt) * 2003-06-30 2006-09-19 Idenix Cayman Ltd sìntese de beta-l-2'-deóxi-nucleosìdeos

Also Published As

Publication number Publication date
EA016838B1 (ru) 2012-07-30
CA2609343C (en) 2015-03-31
BRPI0613796A2 (pt) 2011-02-15
EP1890537A1 (en) 2008-02-27
EP1890537B1 (en) 2012-08-08
CN103735560A (zh) 2014-04-23
JP2008542442A (ja) 2008-11-27
IL187553A0 (en) 2008-03-20
EP1890537A4 (en) 2009-11-11
ES2392544T3 (es) 2012-12-11
JP5149168B2 (ja) 2013-02-20
US8207143B2 (en) 2012-06-26
MX2007015534A (es) 2008-02-25
US7879816B2 (en) 2011-02-01
WO2006133092A1 (en) 2006-12-14
US20080292687A1 (en) 2008-11-27
SG162753A1 (en) 2010-07-29
US20110104108A1 (en) 2011-05-05
NZ563686A (en) 2011-07-29
KR20080017339A (ko) 2008-02-26
AU2006255125B2 (en) 2011-12-08
AU2006255125A1 (en) 2006-12-14
KR101298631B1 (ko) 2013-08-30
CA2609343A1 (en) 2006-12-14
IL187553A (en) 2012-12-31

Similar Documents

Publication Publication Date Title
EA200800002A1 (ru) Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
WO2007067364A3 (en) Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
NZ553405A (en) Nucleoside phosphonate conjugates as anti-HIV agents
PH12018500437B1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
KR102548806B1 (ko) 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체
EA200800047A1 (ru) Производные пиримидина
DK1628685T3 (da) Antivirale phosphonatanaloge
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
AU6422399A (en) 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
TW200510333A (en) Benzimidazole compounds
UY27924A1 (es) Compuestos tipo diarilureas fluoradas
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
WO2004096233A3 (en) Nucleoside phosphonate conjugates
EA201692065A1 (ru) Применение 1,3,5-триазин-2-ил фосфорамидатного соединения в синтезе софосбувира
EA200000847A1 (ru) Противоопухолевые средства
FR2914146B1 (fr) Procede de traitement nematocide des plantes a base d'eugenol et de lecithine(s) et/ou derives
TW200724137A (en) Cancer treatment
UA82322C2 (ru) Использование алкилфосфохолинов в комбинации с противоопухолевыми лекарственными средствами